Symbols / PHIO Stock $1.27 -1.55% Phio Pharmaceuticals Corp.
PHIO (Stock) Chart
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Fundamentals
Scroll to Statements| Market Cap | 14.75M | Enterprise Value | -6.04M | Income | -8.70M | Sales | — | Book/sh | 1.73 | Cash/sh | 1.81 |
| Dividend Yield | — | Payout | 0.00% | Employees | 6 | IPO | — | P/E | — | Forward P/E | -2.05 |
| PEG | — | P/S | — | P/B | 0.73 | P/C | — | EV/EBITDA | 0.66 | EV/Sales | — |
| Quick Ratio | 15.70 | Current Ratio | 16.03 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.45 | EPS next Y | -0.62 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-05 | ROA | -42.33% | ROE | -69.95% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.62M | Shs Float | 11.55M | Short Float | 4.95% |
| Short Ratio | 1.44 | Short Interest | — | 52W High | 4.19 | 52W Low | 0.81 | Beta | 0.81 | Avg Volume | 3.78M |
| Volume | 63.36K | Target Price | $14.00 | Recom | None | Prev Close | $1.29 | Price | $1.27 | Change | -1.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.00
Mean price target
2. Current target
$1.27
Latest analyst target
3. DCF / Fair value
$-7.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.27
Low
$14.00
High
$14.00
Mean
$14.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-02-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
- $PHIO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Mon, 08 Dec 2025 08
- Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan Mon, 16 Mar 2026 07
- Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com ue, 10 Feb 2026 08
- Why Is Phio Pharmaceuticals Stock Up 75% Today? - TipRanks Mon, 03 Nov 2025 08
- Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds - TMX Newsfile Mon, 03 Nov 2025 08
- Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Yahoo Finance Mon, 23 Feb 2026 08
- Phio lines up U.S. supply for skin cancer drug as PH-762 trials advance - Stock Titan Mon, 30 Mar 2026 07
- $PHIO stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 08
- Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - Yahoo Finance ue, 10 Feb 2026 08
- Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan hu, 05 Mar 2026 08
- Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan hu, 09 Apr 2026 07
- Phio reshapes leadership as PH-762 cancer drug nears key tests - Stock Titan hu, 19 Feb 2026 08
- A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan Mon, 23 Mar 2026 07
- Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial - Stock Titan ue, 10 Feb 2026 08
- Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan Wed, 08 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.22
+24.81%
|
7.39
-30.95%
|
10.70
-6.67%
|
11.46
|
| Research And Development |
|
4.62
+26.76%
|
3.64
-42.47%
|
6.33
-9.70%
|
7.01
|
| Selling General And Administration |
|
4.60
+22.92%
|
3.74
-14.25%
|
4.37
-1.89%
|
4.45
|
| General And Administrative Expense |
|
4.60
+22.92%
|
3.74
-14.25%
|
4.37
-1.89%
|
4.45
|
| Other Gand A |
|
4.60
+22.92%
|
3.74
-14.25%
|
4.37
-1.89%
|
4.45
|
| Total Expenses |
|
9.22
+24.81%
|
7.39
-30.95%
|
10.70
-6.67%
|
11.46
|
| Operating Income |
|
-9.22
-24.81%
|
-7.39
+30.95%
|
-10.70
+6.67%
|
-11.46
|
| Total Operating Income As Reported |
|
-9.22
-24.81%
|
-7.39
+31.75%
|
-10.82
+5.57%
|
-11.46
|
| EBITDA |
|
-9.22
-25.37%
|
-7.35
+30.07%
|
-10.51
+6.70%
|
-11.27
|
| Normalized EBITDA |
|
-9.22
-25.37%
|
-7.35
+29.23%
|
-10.39
+7.82%
|
-11.27
|
| Reconciled Depreciation |
|
0.00
-91.43%
|
0.04
-80.98%
|
0.18
-4.66%
|
0.19
|
| EBIT |
|
-9.22
-24.81%
|
-7.39
+30.95%
|
-10.70
+6.67%
|
-11.46
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.13
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.13
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.13
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Net Income |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Pretax Income |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Net Non Operating Interest Income Expense |
|
0.52
+125.11%
|
0.23
+2987.50%
|
-0.01
|
—
|
| Net Interest Income |
|
0.52
+125.11%
|
0.23
+2987.50%
|
-0.01
|
—
|
| Other Income Expense |
|
0.00
-66.67%
|
0.01
+105.00%
|
-0.12
-566.67%
|
-0.02
|
| Other Non Operating Income Expenses |
|
0.00
-66.67%
|
0.01
+0.00%
|
0.01
+133.33%
|
-0.02
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Net Income From Continuing And Discontinued Operation |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Net Income Continuous Operations |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Normalized Income |
|
-8.70
-21.65%
|
-7.15
+33.18%
|
-10.70
+6.79%
|
-11.48
|
| Net Income Common Stockholders |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Diluted EPS |
|
—
|
-9.08
+80.58%
|
-46.76
+48.54%
|
-90.86
|
| Basic EPS |
|
—
|
-9.08
+80.58%
|
-46.76
+48.54%
|
-90.86
|
| Basic Average Shares |
|
—
|
0.79
+240.15%
|
0.23
+83.25%
|
0.13
|
| Diluted Average Shares |
|
—
|
0.79
+240.15%
|
0.23
+83.25%
|
0.13
|
| Diluted NI Availto Com Stockholders |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Total Other Finance Cost |
|
-0.52
-125.11%
|
-0.23
-2987.50%
|
0.01
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
21.49
+274.47%
|
5.74
-38.72%
|
9.36
-26.92%
|
12.81
|
| Current Assets |
|
21.48
+274.41%
|
5.74
-38.47%
|
9.32
-25.10%
|
12.45
|
| Cash Cash Equivalents And Short Term Investments |
|
21.03
+290.77%
|
5.38
-36.61%
|
8.49
-27.93%
|
11.78
|
| Cash And Cash Equivalents |
|
21.03
+290.77%
|
5.38
-36.61%
|
8.49
-27.93%
|
11.78
|
| Cash Financial |
|
21.03
+290.77%
|
5.38
-36.61%
|
8.49
-27.93%
|
11.78
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Other Current Assets |
|
0.45
+25.71%
|
0.35
-57.45%
|
0.83
+35.28%
|
0.61
|
| Total Non Current Assets |
|
0.01
+450.00%
|
0.00
-95.24%
|
0.04
-88.59%
|
0.37
|
| Net PPE |
|
0.01
+450.00%
|
0.00
-94.87%
|
0.04
-88.66%
|
0.34
|
| Gross PPE |
|
0.24
-22.40%
|
0.31
-73.79%
|
1.18
-22.65%
|
1.52
|
| Accumulated Depreciation |
|
-0.23
+25.49%
|
-0.31
+73.06%
|
-1.14
+3.32%
|
-1.18
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.24
-22.40%
|
0.31
-71.90%
|
1.10
-16.46%
|
1.31
|
| Other Properties |
|
—
|
—
|
0.03
-79.50%
|
0.16
|
| Leases |
|
—
|
0.00
-100.00%
|
0.05
+0.00%
|
0.05
|
| Other Non Current Assets |
|
—
|
—
|
0.00
-87.50%
|
0.02
|
| Total Liabilities Net Minority Interest |
|
1.34
+32.02%
|
1.01
-37.88%
|
1.63
-17.31%
|
1.98
|
| Current Liabilities |
|
1.34
+32.02%
|
1.01
-37.88%
|
1.63
-15.73%
|
1.94
|
| Payables And Accrued Expenses |
|
1.34
+32.02%
|
1.01
-26.29%
|
1.38
-1.36%
|
1.40
|
| Payables |
|
0.43
+71.94%
|
0.25
-61.49%
|
0.66
-15.66%
|
0.78
|
| Accounts Payable |
|
0.43
+71.94%
|
0.25
-61.49%
|
0.66
-15.66%
|
0.78
|
| Current Accrued Expenses |
|
0.91
+18.77%
|
0.76
+5.83%
|
0.72
+16.69%
|
0.62
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
0.03
-86.04%
|
0.22
-45.59%
|
0.41
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.04
-74.07%
|
0.14
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.04
-74.07%
|
0.14
|
| Other Current Liabilities |
|
—
|
—
|
—
|
0.02
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Stockholders Equity |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Common Stock Equity |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
—
|
—
|
—
|
—
|
| Share Issued |
|
11.62
+570.58%
|
1.73
+316.08%
|
0.42
+228.99%
|
0.13
|
| Ordinary Shares Number |
|
11.62
+570.58%
|
1.73
+316.08%
|
0.42
+228.99%
|
0.13
|
| Additional Paid In Capital |
|
175.20
+15.97%
|
151.08
+2.82%
|
146.94
+5.54%
|
139.22
|
| Retained Earnings |
|
-155.05
-5.94%
|
-146.36
-5.14%
|
-139.21
-8.43%
|
-128.38
|
| Total Equity Gross Minority Interest |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Total Capitalization |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Working Capital |
|
20.14
+326.52%
|
4.72
-38.59%
|
7.69
-26.83%
|
10.51
|
| Invested Capital |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.04
-79.41%
|
0.17
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.04
-79.41%
|
0.17
|
| Net Tangible Assets |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Tangible Book Value |
|
20.15
+326.57%
|
4.72
-38.90%
|
7.73
-28.68%
|
10.84
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.98
-12.19%
|
-7.11
+33.84%
|
-10.75
+11.38%
|
-12.13
|
| Cash Flow From Continuing Operating Activities |
|
-7.98
-12.19%
|
-7.11
+33.84%
|
-10.75
+11.38%
|
-12.13
|
| Net Income From Continuing Operations |
|
-8.70
-21.65%
|
-7.15
+33.96%
|
-10.83
+5.70%
|
-11.48
|
| Depreciation Amortization Depletion |
|
0.00
-91.43%
|
0.04
-80.98%
|
0.18
-4.66%
|
0.19
|
| Depreciation |
|
0.00
-91.43%
|
0.04
-80.98%
|
0.18
-4.66%
|
0.19
|
| Depreciation And Amortization |
|
0.00
-91.43%
|
0.04
-80.98%
|
0.18
-4.66%
|
0.19
|
| Other Non Cash Items |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.48
+227.21%
|
0.15
-51.49%
|
0.30
-26.81%
|
0.41
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Operating Gains Losses |
|
—
|
-0.01
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Change In Working Capital |
|
0.23
+270.29%
|
-0.14
+74.25%
|
-0.54
+57.32%
|
-1.26
|
| Change In Prepaid Assets |
|
-0.09
-118.92%
|
0.48
+345.41%
|
-0.20
-2550.00%
|
0.01
|
| Change In Payables And Accrued Expense |
|
0.33
+155.82%
|
-0.58
-184.88%
|
-0.20
+82.00%
|
-1.14
|
| Change In Accrued Expense |
|
0.14
+179.44%
|
-0.18
-116.87%
|
-0.08
+94.92%
|
-1.64
|
| Change In Payable |
|
0.18
+145.30%
|
-0.40
-231.15%
|
-0.12
-124.60%
|
0.50
|
| Change In Account Payable |
|
0.18
+145.30%
|
-0.40
-231.15%
|
-0.12
-124.60%
|
0.50
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.04
+74.07%
|
-0.14
-8.00%
|
-0.12
|
| Investing Cash Flow |
|
-0.01
-250.00%
|
0.01
+260.00%
|
-0.01
+95.87%
|
-0.12
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-250.00%
|
0.01
+260.00%
|
-0.01
+95.87%
|
-0.12
|
| Net PPE Purchase And Sale |
|
-0.01
-1100.00%
|
-0.00
+80.00%
|
-0.01
+95.87%
|
-0.12
|
| Purchase Of PPE |
|
-0.01
-1100.00%
|
-0.00
+80.00%
|
-0.01
+95.87%
|
-0.12
|
| Capital Expenditure |
|
-0.01
-1100.00%
|
-0.00
+80.00%
|
-0.01
+95.87%
|
-0.12
|
| Net Other Investing Changes |
|
—
|
0.01
|
—
|
—
|
| Financing Cash Flow |
|
23.64
+491.59%
|
4.00
-46.09%
|
7.41
+28611.54%
|
-0.03
|
| Cash Flow From Continuing Financing Activities |
|
23.64
+491.59%
|
4.00
-46.09%
|
7.41
+28611.54%
|
-0.03
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
17.91
+1791600.00%
|
-0.00
-100.01%
|
7.44
|
0.00
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.00
+90.91%
|
-0.01
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.00
+92.31%
|
-0.01
|
0.00
|
| Proceeds From Stock Option Exercised |
|
5.75
+43.80%
|
4.00
|
—
|
0.00
|
| Net Other Financing Charges |
|
-0.03
-500.00%
|
-0.01
+80.77%
|
-0.03
+7.14%
|
-0.03
|
| Changes In Cash |
|
15.65
+603.51%
|
-3.11
+6.97%
|
-3.34
+72.78%
|
-12.28
|
| Beginning Cash Position |
|
5.38
-36.61%
|
8.49
-28.24%
|
11.83
-50.92%
|
24.11
|
| End Cash Position |
|
21.03
+290.77%
|
5.38
-36.61%
|
8.49
-28.24%
|
11.83
|
| Free Cash Flow |
|
-7.99
-12.34%
|
-7.11
+33.86%
|
-10.75
+12.21%
|
-12.25
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
+18.18%
|
0.01
|
—
|
| Common Stock Issuance |
|
17.91
|
0.00
-100.00%
|
7.45
|
0.00
|
| Issuance Of Capital Stock |
|
17.91
|
0.00
-100.00%
|
7.45
+372500.00%
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
0.00
+100.00%
|
-0.00
-200.00%
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Preferred Stock Payments |
|
—
|
0.00
+100.00%
|
-0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-08 View
- 8-K2026-03-30 View
- 10-K2026-03-05 View
- 8-K2026-03-05 View
- 8-K2026-02-18 View
- 8-K2026-02-10 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 8-K2026-01-20 View
- 42026-01-02 View
- 42025-12-29 View
- 8-K2025-12-23 View
- 8-K2025-11-25 View
- 42025-11-24 View
- 42025-11-19 View
- 10-Q2025-11-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|